Tuberculosis Clinical Trial Landscape
Data updated: May 20, 2026
470 clinical trials tracked since 2008
Tuberculosis is being studied across 470 clinical trials registered since 2008, with 95 programs currently active. The competitive pipeline includes 40 active Phase 3 trials, 43 active Phase 2 trials, and 17 active Phase 1 trials. Top industry sponsors include Shanghai Jiatan Pharmatech Co., Ltd, Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc..
95 active
/
470 total (since 2008)
17
Phase 1 Active
146 total
43
Phase 2 Active
207 total
40
Phase 3 Active
115 total
11
Phase 4 Active
51 total
Top Industry Sponsors
Sorted by active Active Done Failed
Shanghai Jiatan Pharmatech Co., Ltd 3 1 0
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 2 14 1
Otsuka Pharmaceutical Development & Commercialization, Inc. 1 7 1
Biofabri, S.L 1 3 0
Bharat Biotech International Limited 1 1 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06568484 RECRUITING
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
Johns Hopkins University n=2,530
NCT06498414 RECRUITING
Shorter and Safer Treatment Regimens for Latent TB
McGill University Health Centre/Research Institute of the McGill University Health Centre n=1,800
NCT03474029 RECRUITING
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
Centers for Disease Control and Prevention n=3,400
NCT07209761 RECRUITING
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc. n=532
NCT06062238 ACTIVE NOT RECRUITING
Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults
Gates Medical Research Institute n=20,080
+ 110 more Phase 3 trials — see full database below
Tuberculosis — Trials Started by Year (last 10 years)
2016 23
2017 25
2018 14
2019 26
2020 27
2021 21
2022 25
2023 29
2024 21
2025 28
2026 16
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Shanghai Jiatan Pharmatech Co., Ltd 4
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 17
Otsuka Pharmaceutical Development & Commercialization, Inc. 9
Biofabri, S.L 4
Bharat Biotech International Limited 2
BioNTech SE 2
Chengdu CoenBiotech Co., Ltd 2
Johnson & Johnson 1
CanSino Biologics Inc. 1
BioVersys AG 1
Active Trials by Phase
Phase 1 17
Phase 2 43
Phase 3 40
Phase 4 11
Enrollment Size Distribution
1-50 153
51-200 155
201-500 65
501-1k 39
1k+ 46
All Industry Sponsors
Sorted by active Active Done Failed
Shanghai Jiatan Pharmatech Co., Ltd 3 1 0
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 2 14 1
Otsuka Pharmaceutical Development & Commercialization, Inc. 1 7 1
Biofabri, S.L 1 3 0
Bharat Biotech International Limited 1 1 0
BioNTech SE 1 1 0
Chengdu CoenBiotech Co., Ltd 1 1 0
Johnson & Johnson 1 0 0
CanSino Biologics Inc. 1 0 0
BioVersys AG 1 0 0
WestVac Biopharma Co., Ltd. 1 0 0
Quratis Inc. 1 0 0
GSK 0 12 2
Archivel Farma S.L. 0 3 2
Serum Institute of India Pvt. Ltd. 0 3 0
NCT06568484 RECRUITING
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
Johns Hopkins University n=2,530
NCT06498414 RECRUITING
Shorter and Safer Treatment Regimens for Latent TB
McGill University Health Centre/Research Institute of the McGill University Health Centre n=1,800
NCT03474029 RECRUITING
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
Centers for Disease Control and Prevention n=3,400
NCT07209761 RECRUITING
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc. n=532
NCT06062238 ACTIVE NOT RECRUITING
Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults
Gates Medical Research Institute n=20,080
NCT06253715 RECRUITING
Shortened Regimen for Drug-susceptible TB in Children
Johns Hopkins University n=860
NCT07486024 NOT YET RECRUITING
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
Assistance Publique - Hôpitaux de Paris n=55
NCT06441006 RECRUITING
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
University of California, San Francisco n=400
NCT07332325 NOT YET RECRUITING
STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis
University of Virginia n=344
NCT04951986 ACTIVE NOT RECRUITING
Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis
University of Cape Town n=732
NCT06022146 RECRUITING
TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts
Huashan Hospital n=3,520
NCT07268664 NOT YET RECRUITING
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort
Beijing Chest Hospital n=120
NCT06497465 RECRUITING
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
Johns Hopkins University n=150
NCT05766267 ACTIVE NOT RECRUITING
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Centers for Disease Control and Prevention n=288
NCT05473520 RECRUITING
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
National University Hospital, Singapore n=150
NCT07163143 NOT YET RECRUITING
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
University College, London n=784
NCT07152639 RECRUITING
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
Chengdu CoenBiotech Co., Ltd n=1,784
NCT06649721 ACTIVE NOT RECRUITING
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
Huashan Hospital n=120
NCT07136987 NOT YET RECRUITING
A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery
Open Source Pharma Foundation n=1,104
NCT07118696 NOT YET RECRUITING
Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease
Hamilton Health Sciences Corporation n=1,000
NCT07076225 NOT YET RECRUITING
Ultra-Short Regimen for Elderly DS-TB
Shenzhen Third People's Hospital n=300
NCT05824871 RECRUITING
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
Shanghai Jiatan Pharmatech Co., Ltd n=450
NCT03568383 ACTIVE NOT RECRUITING
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
National Institute of Allergy and Infectious Diseases (NIAID) n=5,832
NCT05686356 ACTIVE NOT RECRUITING
A Pan-TB Regimen Targeting Host and Microbe
The Aurum Institute NPC n=352
NCT04260477 RECRUITING
Novel Triple-dose Tuberculosis Retreatment Regimen
Institute of Tropical Medicine, Belgium n=370
NCT05081401 RECRUITING
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
Huashan Hospital n=1,050
NCT06081361 ACTIVE NOT RECRUITING
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Beijing Chest Hospital n=186
NCT06727864 RECRUITING
Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial
Kaohsiung Veterans General Hospital. n=270
NCT06191692 NOT YET RECRUITING
1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam
Freundeskreis Für Internationale Tuberkulosehilfe e.V n=350
NCT04975178 RECRUITING
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Biofabri, S.L n=7,120
NCT06618573 RECRUITING
Safety of Administering Isoniazid to SLE Patients to Prevent TB
Universitas Padjadjaran n=60
NCT04147286 RECRUITING
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
University of Cape Town n=220
NCT06526039 NOT YET RECRUITING
A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB
Taipei Medical University WanFang Hospital n=100
NCT04856644 ACTIVE NOT RECRUITING
Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB
Kaohsiung Veterans General Hospital. n=333
NCT05401071 RECRUITING
Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)
Huashan Hospital n=2,442
NCT05454345 NOT YET RECRUITING
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
First Affiliated Hospital of Zhejiang University n=620
NCT04485156 NOT YET RECRUITING
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
Seoul National University Hospital n=926
NCT05899179 COMPLETED
Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=780
NCT04453293 TERMINATED
Immunization With BCG Vaccine to Prevent Tuberculosis Infection
Henry M. Jackson Foundation for the Advancement of Military Medicine n=16
NCT04738812 COMPLETED
Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression
ANRS, Emerging Infectious Diseases n=1,330
NCT03915366 COMPLETED
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
Hospital Universitario 12 de Octubre n=563
NCT02563327 COMPLETED
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
Centers for Disease Control and Prevention n=53
NCT02333799 COMPLETED
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
Global Alliance for TB Drug Development n=109
NCT03100786 COMPLETED
Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis
Oxford University Clinical Research Unit, Vietnam n=702
NCT03152903 COMPLETED
Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence
Serum Institute of India Pvt. Ltd. n=2,000
NCT01582711 COMPLETED
Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
Centers for Disease Control and Prevention n=1,002
NCT02754765 COMPLETED
Evaluating Newly Approved Drugs for Multidrug-resistant TB
Médecins Sans Frontières, France n=754
NCT03896685 COMPLETED
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Médecins Sans Frontières, France n=323
NCT04351685 COMPLETED
Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
Serum Institute of India Pvt. Ltd. n=6,940
NCT02410772 COMPLETED
TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
Centers for Disease Control and Prevention n=2,516
NCT04062201 COMPLETED
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
Wits Health Consortium (Pty) Ltd n=402
NCT04121195 COMPLETED
Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load
University of Liverpool n=26
NCT02589782 COMPLETED
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
Medecins Sans Frontieres, Netherlands n=552
NCT04207112 COMPLETED
Economic Evaluation of New MDR TB Regimens
Medecins Sans Frontieres, Netherlands n=73
NCT03092817 COMPLETED
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
Oxford University Clinical Research Unit, Vietnam n=520
NCT03338621 COMPLETED
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
Global Alliance for TB Drug Development n=455
NCT04094012 COMPLETED
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
National Taiwan University Hospital n=490
NCT05330884 SUSPENDED
BCG Revaccination in Children and Adolescents
Tuberculosis Research Centre, India n=9,200
NCT04721795 COMPLETED
Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)
Obafemi Awolowo University Teaching Hospital n=150
NCT02409290 COMPLETED
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
IUATLD, Inc n=588
NCT03474198 COMPLETED
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
University College, London n=675
NCT03086486 COMPLETED
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
Global Alliance for TB Drug Development n=181
NCT02581527 COMPLETED
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
St George's, University of London n=672
NCT03947138 COMPLETED
A Study of GC3107(BCG Vaccine) in Healthy Infants
Green Cross Corporation n=750
NCT02880982 COMPLETED
Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren
Queen Mary University of London n=1,743
NCT02467608 COMPLETED
Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis
Orient Pharma Co., Ltd. n=557
NCT02607449 COMPLETED
FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis
Scientific Center for Anti-infectious Drugs, Kazakhstan n=344
NCT01404312 COMPLETED
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
National Institute of Allergy and Infectious Diseases (NIAID) n=3,000
NCT02454205 COMPLETED
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
University of Cape Town n=154
NCT03545373 COMPLETED
Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
London School of Hygiene and Tropical Medicine n=1,583
NCT04285905 TERMINATED
Male Partner-assisted Contact Tracing for HIV and Tuberculosis in Malawi
Liverpool School of Tropical Medicine n=30
NCT02795260 COMPLETED
Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=1,802
NCT02276755 COMPLETED
Vitamin D Supplementation in TB Prevention
Harvard School of Public Health (HSPH) n=8,851
NCT02430259 COMPLETED
Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention
Huashan Hospital n=566
NCT03862248 WITHDRAWN
Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
Institute of Tropical Medicine, Belgium
NCT02980016 COMPLETED
Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals
The Aurum Institute NPC n=4,027
NCT01424670 COMPLETED
Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc. n=511
NCT00933790 COMPLETED
Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
Tuberculosis Research Centre, India n=331
NCT02342886 COMPLETED
Shortening Treatment by Advancing Novel Drugs
Global Alliance for TB Drug Development n=284
NCT02273765 COMPLETED
Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
ANRS, Emerging Infectious Diseases n=460
NCT01979900 COMPLETED
Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=10,000
NCT02623556 COMPLETED
Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=1,090
NCT03027154 COMPLETED
Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=96
NCT01924286 COMPLETED
Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone
University of Cape Town n=240
NCT00931736 COMPLETED
Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness
McGill University n=6,031
NCT00170209 COMPLETED
Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)
McGill University n=844
NCT01517022 COMPLETED
Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis
All India Institute of Medical Sciences n=800
NCT02975570 WITHDRAWN
Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin
Boston University
NCT02169882 COMPLETED
High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study
Universitas Padjadjaran n=60
NCT00864383 COMPLETED
Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis
Global Alliance for TB Drug Development n=1,931
NCT01642888 COMPLETED
A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI
Statens Serum Institut n=1,190
NCT00801606 COMPLETED
Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis
All India Institute of Medical Sciences n=403
NCT01589289 COMPLETED
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
Institute of Tropical Medicine, Belgium n=352
NCT01600963 WITHDRAWN
A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis
Janssen Infectious Diseases BVBA
NCT01778062 COMPLETED
Indacaterol EfectIveness In COPD Patients With Tuberculosis History
Novartis Pharmaceuticals n=136
NCT01124929 COMPLETED
Treatment Duration for Abdominal Tuberculosis
All India Institute of Medical Sciences n=197
NCT00495651 COMPLETED
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
French National Agency for Research on AIDS and Viral Hepatitis n=2,073
NCT01061593 COMPLETED
Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV
Lisichansk Regional Tuberculosis Dispensary n=269
NCT01779102 COMPLETED
Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses
Statens Serum Institut n=456
NCT01631266 COMPLETED
Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI
Statens Serum Institut n=979
NCT01955824 COMPLETED
A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy
Post Graduate Institute of Medical Education and Research, Chandigarh n=500
NCT01761201 TERMINATED
"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla n=68
NCT01442428 WITHDRAWN
Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial
University of Minnesota
NCT01722396 COMPLETED
Pharmacogenetics of Vitamin D Supplementation in Tuberculosis
University of Birmingham n=62
NCT01055145 TERMINATED
Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients
Seoul National University Hospital n=182
NCT00366470 COMPLETED
A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients
Peter Daley n=250
NCT00677339 COMPLETED
L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)
Menzies School of Health Research n=200
NCT00571753 TERMINATED
Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)
University of Cologne n=900
NCT00767975 COMPLETED
Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison
National Taiwan University Hospital n=2,384
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only